- Home
- ANAB vs CRMD Comparison
ANAB vs CRMD Comparison
Compare ANAB & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CRMD
- Stock Information
- Founded
- ANAB 2005
- CRMD 2006
- Country
- ANAB United States
- CRMD United States
- Employees
- ANAB N/A
- CRMD N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- CRMD Health Care
- Exchange
- ANAB Nasdaq
- CRMD Nasdaq
- Market Cap
- ANAB 759.5M
- CRMD 645.0M
- IPO Year
- ANAB 2017
- CRMD 2010
- Fundamental
- Price
- ANAB $18.59
- CRMD $10.13
- Analyst Decision
- ANAB Buy
- CRMD Strong Buy
- Analyst Count
- ANAB 12
- CRMD 6
- Target Price
- ANAB $41.20
- CRMD $15.67
- AVG Volume (30 Days)
- ANAB 1.4M
- CRMD 906.0K
- Earning Date
- ANAB 03-10-2025
- CRMD 03-11-2025
- Dividend Yield
- ANAB N/A
- CRMD N/A
- EPS Growth
- ANAB N/A
- CRMD N/A
- EPS
- ANAB N/A
- CRMD N/A
- Revenue
- ANAB $57,172,000.00
- CRMD $12,262,234.00
- Revenue This Year
- ANAB $229.13
- CRMD N/A
- Revenue Next Year
- ANAB N/A
- CRMD $234.92
- P/E Ratio
- ANAB N/A
- CRMD N/A
- Revenue Growth
- ANAB 282.17
- CRMD 41184.20
- 52 Week Low
- ANAB $12.21
- CRMD $3.03
- 52 Week High
- ANAB $41.31
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- ANAB 55.28
- CRMD 44.90
- Support Level
- ANAB $12.21
- CRMD $9.79
- Resistance Level
- ANAB $21.57
- CRMD $11.28
- Average True Range (ATR)
- ANAB 1.72
- CRMD 0.51
- MACD
- ANAB 0.39
- CRMD -0.05
- Stochastic Oscillator
- ANAB 68.16
- CRMD 23.84
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.